The blinatumomab is a CD3-CD19 bispecific antibody that binds and transports CD3+ T cells to CD19+ B-cell in acute lymphoblastic leukemia and several groups have developed multivalent targeting molecules that specifically engage in the vicinity of the target tumor NK cells to enhance tumor killing (115). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.